Optimal sequencing strategies for identifying disease-associated singletons

Sara Rashkin, Goo Jun, Sai Chen, Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) and Goncalo R Abecasis

PLOS Genetics, 2017, vol. 13, issue 6, 1-16

Abstract: With the increasing focus of genetic association on the identification of trait-associated rare variants through sequencing, it is important to identify the most cost-effective sequencing strategies for these studies. Deep sequencing will accurately detect and genotype the most rare variants per individual, but may limit sample size. Low pass sequencing will miss some variants in each individual but has been shown to provide a cost-effective alternative for studies of common variants. Here, we investigate the impact of sequencing depth on studies of rare variants, focusing on singletons—the variants that are sampled in a single individual and are hardest to detect at low sequencing depths. We first estimate the sensitivity to detect singleton variants in both simulated data and in down-sampled deep genome and exome sequence data. We then explore the power of association studies comparing burden of singleton variants in cases and controls under a variety of conditions. We show that the power to detect singletons increases with coverage, typically plateauing for coverage > ~25x. Next, we show that, when total sequencing capacity is fixed, the power of association studies focused on singletons is typically maximized for coverage of 15-20x, independent of relative risk, disease prevalence, singleton burden, and case-control ratio. Our results suggest sequencing depth of 15-20x as an appropriate compromise of singleton detection power and sample size for studies of rare variants in complex disease.Author summary: Genetic studies of rare variants can help us understand the biology of human disease. With modern techniques and sufficient effort, it is possible to very accurately resolve any human genome, identifying most of its unique features. When funding is limited, applying these techniques to study human disease often involves a trade-off between examining more samples, at reduced accuracy per sample, or fewer samples, each at greater accuracy. We evaluate these trade-offs for studies of very rare variants, using both simulation and real data. We propose cost effective strategies for increasing our understanding of human disease.

Date: 2017
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1006811 (text/html)
https://journals.plos.org/plosgenetics/article/fil ... 06811&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pgen00:1006811

DOI: 10.1371/journal.pgen.1006811

Access Statistics for this article

More articles in PLOS Genetics from Public Library of Science
Bibliographic data for series maintained by plosgenetics ().